Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus
The investigation of biomarkers for metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH) reveals their potential for advancing disease treatment and addressing their notable overlap. The connection between MASH, obesity, and T2DM high...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/2/359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719330269298688 |
|---|---|
| author | Sulagna Mukherjee Seung-Soon Im |
| author_facet | Sulagna Mukherjee Seung-Soon Im |
| author_sort | Sulagna Mukherjee |
| collection | DOAJ |
| description | The investigation of biomarkers for metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH) reveals their potential for advancing disease treatment and addressing their notable overlap. The connection between MASH, obesity, and T2DM highlights the need for an integrative management approach addressing mechanisms like insulin resistance and chronic inflammation. Obesity contributes significantly to the development of MASH through lipid dysregulation, insulin resistance, and chronic inflammation. Selective biomarker targeting offers a valuable strategy for detecting these comorbidities. Biomarkers such as CRP, IL-6, and TNF-α serve as indicators of inflammation, while HOMA-IR, fasting insulin, and HbA1c are essential for evaluating insulin resistance. Additionally, triglycerides, LDL, and HDL are crucial for comprehending lipid dysregulation. Despite the growing importance of digital biomarkers, challenges in research methodologies and sample variability persist, necessitating further studies to validate diagnostic tools and improve health interventions. Future opportunities include developing non-invasive biomarker panels, using multiomics, and using machine learning to enhance prognoses for diagnostic accuracy and therapeutic outcomes. |
| format | Article |
| id | doaj-art-4f7f238d121b43f1be66a013140ff093 |
| institution | DOAJ |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-4f7f238d121b43f1be66a013140ff0932025-08-20T03:12:10ZengMDPI AGBiomedicines2227-90592025-02-0113235910.3390/biomedicines13020359Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes MellitusSulagna Mukherjee0Seung-Soon Im1Department of Physiology, Keimyung University School of Medicine, Daegu 42601, Republic of KoreaDepartment of Physiology, Keimyung University School of Medicine, Daegu 42601, Republic of KoreaThe investigation of biomarkers for metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH) reveals their potential for advancing disease treatment and addressing their notable overlap. The connection between MASH, obesity, and T2DM highlights the need for an integrative management approach addressing mechanisms like insulin resistance and chronic inflammation. Obesity contributes significantly to the development of MASH through lipid dysregulation, insulin resistance, and chronic inflammation. Selective biomarker targeting offers a valuable strategy for detecting these comorbidities. Biomarkers such as CRP, IL-6, and TNF-α serve as indicators of inflammation, while HOMA-IR, fasting insulin, and HbA1c are essential for evaluating insulin resistance. Additionally, triglycerides, LDL, and HDL are crucial for comprehending lipid dysregulation. Despite the growing importance of digital biomarkers, challenges in research methodologies and sample variability persist, necessitating further studies to validate diagnostic tools and improve health interventions. Future opportunities include developing non-invasive biomarker panels, using multiomics, and using machine learning to enhance prognoses for diagnostic accuracy and therapeutic outcomes.https://www.mdpi.com/2227-9059/13/2/359biomarkersobesityMASHtype 2 diabetesmetabolic disorder |
| spellingShingle | Sulagna Mukherjee Seung-Soon Im Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus Biomedicines biomarkers obesity MASH type 2 diabetes metabolic disorder |
| title | Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus |
| title_full | Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus |
| title_fullStr | Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus |
| title_full_unstemmed | Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus |
| title_short | Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus |
| title_sort | decoding health exploring essential biomarkers linked to metabolic dysfunction associated steatohepatitis and type 2 diabetes mellitus |
| topic | biomarkers obesity MASH type 2 diabetes metabolic disorder |
| url | https://www.mdpi.com/2227-9059/13/2/359 |
| work_keys_str_mv | AT sulagnamukherjee decodinghealthexploringessentialbiomarkerslinkedtometabolicdysfunctionassociatedsteatohepatitisandtype2diabetesmellitus AT seungsoonim decodinghealthexploringessentialbiomarkerslinkedtometabolicdysfunctionassociatedsteatohepatitisandtype2diabetesmellitus |